Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALXO

Alx Oncology Holdings Inc

Dec 01 • 04:00PM ET

8.01

Dollar change +0.17
Percentage change 2.17	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.57	Insider Own	55.28%	Shs Outstand	40.86M	Perf Week	-9.39%
Market Cap	399.06M	Forward P/E	-	EPS next Y	-3.30	Insider Trans	-0.05%	Shs Float	22.28M	Perf Month	10.64%
Income	-146.04M	PEG	-	EPS next Q	-0.84	Inst Own	43.72%	Short Float / Ratio	17.52% / 3.05	Perf Quarter	77.21%
Sales	0.00M	P/S	-	EPS this Y	-13.57%	Inst Trans	1.08%	Short Interest	3.90M	Perf Half Y	-3.73%
Book/sh	4.10	P/B	1.95	EPS next Y	4.11%	ROA	-54.31%	Target Price	15.25	Perf Year	-27.84%
Cash/sh	3.81	P/C	2.10	EPS next 5Y	-	ROE	-64.09%	52W Range	3.94 - 12.33	Perf YTD	-28.93%
Dividend	-	P/FCF	-	EPS past 5Y	-58.82%	ROI	-79.82%	52W High	-35.04%	Beta	1.39
Dividend %	-	Quick Ratio	5.66	Sales past 5Y	-10.83%	Gross Margin	-	52W Low	103.52%	ATR	0.77
Employees	58	Current Ratio	5.66	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	46.60	Volatility	9.12% 9.50%
Optionable	Yes	Debt/Eq	0.09	EPS Q/Q	-42.96%	Profit Margin	-	Rel Volume	0.26	Prev Close	7.84
Shortable	Yes	LT Debt/Eq	0.08	Earnings	Nov 13 AMC	Payout	-	Avg Volume	1.28M	Price	8.01
Recom	1.29	SMA20	-8.06%	SMA50	4.58%	SMA200	24.80%	Volume	333,945	Change	2.17%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$65 → $25
Sep-30-21	Initiated	Stifel	Buy	$106
May-05-21	Resumed	Credit Suisse	Outperform	$98
Apr-26-21	Resumed	Credit Suisse	Outperform	$98
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy	$100
Aug-11-20	Initiated	Piper Sandler	Overweight	$55
Aug-11-20	Initiated	Jefferies	Buy	$50
Aug-11-20	Initiated	Credit Suisse	Outperform	$53
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight	$64

Nov-13-23 04:47PM	ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com) +8.08%
04:05PM	ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-23 04:05PM	ALX Oncology Announces November Investor Conference Participation (GlobeNewswire)
Oct-10-23 04:05PM	ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +16.24%
Oct-06-23 04:59AM	The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna (Zacks) +27.38%
10:58AM	Loading…
Oct-05-23 10:58AM	Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More (Zacks)
08:00AM	ALX Oncology Announces Pricing of Public Offering (GlobeNewswire)
Oct-04-23 04:10PM	ALX Oncology Announces Proposed Public Offering (GlobeNewswire) -15.05%
11:39AM	ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data (Zacks)
Oct-03-23 11:15AM	Why ALX Oncology Stock Is Skyrocketing Today (Motley Fool) +56.13%
09:36AM	Midday movers: McCormick Airbnb, Point Biopharma and more (Investing.com)
06:00AM	ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Oct-02-23 04:05PM	ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Sep-06-23 08:00AM	ALX Oncology Realigns Executive Leadership Team (GlobeNewswire) +6.37%
Aug-31-23 07:00AM	ALX Oncology Announces September Investor Conference Participation (GlobeNewswire)
07:31PM	Loading…
Aug-14-23 07:31PM	While dollars continue to flow into biotech, companies cut more jobs (American City Business Journals)
Aug-10-23 04:01PM	ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update (GlobeNewswire)
09:55AM	ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jun-26-23 07:00AM	ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer (GlobeNewswire)
May-11-23 04:01PM	ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
May-09-23 07:00AM	ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer (GlobeNewswire) +6.36%
Apr-25-23 07:00AM	ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma (GlobeNewswire)
Apr-19-23 11:36AM	These 2 Strong Buy Penny Stocks Could Rally to $40 (or More), Says Piper Sandler (TipRanks) +6.44%
Mar-14-23 08:00AM	ALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer (PR Newswire) -6.75%
Mar-13-23 07:00AM	ALX Oncology and Quantum Leap Healthcare Collaborative Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer (GlobeNewswire)
Mar-09-23 04:01PM	ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones (GlobeNewswire) -5.93%
Feb-16-23 07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer (GlobeNewswire)
Jan-05-23 07:00AM	ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023 (GlobeNewswire)
Jan-03-23 07:00AM	ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-22 10:00AM	ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia (GlobeNewswire) +5.12%
07:00AM	Loading…
Nov-29-22 07:00AM	ALX Oncology Appoints Scott Garland to its Board of Directors (GlobeNewswire) +7.25%
Nov-08-22 04:01PM	ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
Nov-03-22 09:00AM	ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting (GlobeNewswire)
Nov-02-22 07:00AM	ALX Oncology Announces Upcoming Investor Conference Participation (GlobeNewswire)
Oct-31-22 07:00AM	ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept (GlobeNewswire)
Oct-05-22 08:01AM	ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (GlobeNewswire)
Sep-21-22 04:01PM	ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference (GlobeNewswire)
Sep-01-22 07:00AM	ALX Oncology Announces Upcoming Investor Conference Participation (GlobeNewswire)
Aug-16-22 09:45AM	ALX Oncology and Quantum Leap Healthcare Collaborative Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer (PR Newswire)
Aug-15-22 07:00AM	ALX Oncology and Quantum Leap Healthcare Collaborative Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer (GlobeNewswire)
Aug-11-22 07:00AM	ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer (GlobeNewswire)
Aug-08-22 04:01PM	ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
Aug-01-22 07:00AM	ALX Oncologys Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Jun-29-22 08:44AM	ALX's stock is up 11% after getting orphan-drug designation for cancer drug (MarketWatch)
07:00AM	ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia (GlobeNewswire)
Jun-22-22 09:00AM	Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference (GlobeNewswire)
Jun-03-22 07:00AM	ALX Oncology Announces Evorpacept Clinical Program Updates (GlobeNewswire)
Jun-01-22 07:00AM	ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference (GlobeNewswire)
Apr-12-22 07:00AM	ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors (GlobeNewswire)
Mar-02-22 07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer (GlobeNewswire)
Feb-28-22 07:00AM	ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones (GlobeNewswire) +7.54%
Feb-03-22 07:01PM	3 Strong Buy Small-Cap Stocks That Are Too Cheap to Ignore (TipRanks) -5.08%
Feb-02-22 01:38PM	HC Advisors, LLC Buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, ... (GuruFocus.com) -11.83%
Jan-28-22 12:44PM	ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC (Zacks) +5.85%
08:02AM	ALX Oncology's Evorpacept Gets Orphan Drug Tag For Gastric Cancer (Benzinga)
Jan-27-22 05:51PM	ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer (GlobeNewswire)
Jan-19-22 06:23AM	New Strong Sell Stocks for January 19th (Zacks)
Jan-10-22 06:00AM	ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022 (GlobeNewswire)
Jan-04-22 07:00AM	ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.62%
Dec-14-21 09:00AM	DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia (PR Newswire)
Dec-13-21 01:58PM	ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation (Benzinga) -24.20%
Dec-12-21 09:00AM	ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome (GlobeNewswire)
Nov-11-21 04:05PM	ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
Nov-09-21 11:13AM	ALX Oncology Falls After Updated Data For Solid Tumors Candidate (Benzinga) -21.47%
07:00AM	ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid Tumors (GlobeNewswire)
Nov-04-21 09:00AM	ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting (GlobeNewswire) -15.47%
Nov-02-21 09:00AM	ALX Oncology Announces Upcoming Virtual Investor Conference Participation (GlobeNewswire)
Oct-21-21 11:19AM	President And CEO Of Alx Oncology Holdings Sold $910K In Stock (Benzinga)
07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia (GlobeNewswire)
Oct-07-21 07:00AM	ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio (GlobeNewswire) -6.68%
Oct-01-21 08:00AM	ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (GlobeNewswire)
Sep-16-21 07:00AM	ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma (GlobeNewswire)
Sep-14-21 07:00AM	Lightstone Ventures Raises $375 Million Fund (PR Newswire)
Sep-07-21 07:00AM	ALX Oncology Announces Upcoming Virtual Investor Conference Participation (GlobeNewswire)
Aug-27-21 06:55AM	The 3 Best Biotech Stocks to Buy Right Now (Motley Fool)
Aug-12-21 04:05PM	ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
Jul-28-21 07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Jul-15-21 12:00PM	ALX Oncology Holdings Inc. (ALXO) Upgraded to Buy: Here's What You Should Know (Zacks)
01:36AM	Read This Before Selling ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares (Simply Wall St.)
Jul-12-21 06:07AM	ALX Oncology (ALXO) Sees Hammer Chart Pattern: Time to Buy? (Zacks)
Jul-06-21 09:15AM	ALX Oncology Shares Jump As ALX148 Shows ORR of 72% In Patients With HER2 Positive Stomach Cancer (Benzinga) +9.70%
Jul-03-21 07:15AM	ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer (GlobeNewswire)
Jun-14-21 07:00AM	ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies (GlobeNewswire)
Jun-10-21 07:00AM	ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer (GlobeNewswire)
May-18-21 07:00AM	ALX Oncology Announces Upcoming Virtual Investor Conference Participation (GlobeNewswire)
May-17-21 04:05PM	ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
May-10-21 07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma (GlobeNewswire) -5.03%
Apr-21-21 04:05PM	ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer (GlobeNewswire) +6.54%
Apr-16-21 01:41AM	Companies Like ALX Oncology Holdings (NASDAQ:ALXO) Are In A Position To Invest In Growth (Simply Wall St.)
Apr-05-21 07:00AM	ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148 (GlobeNewswire)
Mar-18-21 04:05PM	ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones (GlobeNewswire) -9.78%
Mar-15-21 07:00AM	ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors (GlobeNewswire)
Mar-05-21 08:15AM	The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study (Benzinga) -15.51%
Mar-04-21 04:05PM	ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics (GlobeNewswire)
Mar-03-21 08:34AM	Why Earnings Season Could Be Great for ALX Oncology (ALXO) (Zacks)
Mar-02-21 07:00AM	ALX Oncology to Participate at H.C. Wainwright Global Life Sciences Conference (GlobeNewswire)
Feb-10-21 10:05AM	Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021 (Benzinga)
Jan-16-21 01:12AM	Have Insiders Been Buying ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares This Year? (Simply Wall St.)
Jan-11-21 07:00AM	ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021 (GlobeNewswire)
Jan-05-21 07:00AM	ALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.19%

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pinto Shelly	VP, Finance and CAO	Jul 06	Sale	6.52	7,345	47,889	55,713	Jul 07 04:09 PM
Pons Jaume	President & CEO	Jun 30	Sale	7.34	3,208	23,547	536,538	Jul 05 05:07 PM
Randolph Sophia	Chief Medical Officer	Jun 30	Sale	7.34	1,605	11,781	281,477	Jul 05 05:09 PM
GARCIA PETER S	Chief Financial Officer	Jun 30	Sale	7.34	887	6,511	54,738	Jul 05 05:00 PM
Pinto Shelly	VP, Finance and CAO	Jun 30	Sale	7.34	466	3,420	63,058	Jul 05 05:05 PM
Randolph Sophia	Chief Medical Officer	Jun 09	Option Exercise	3.75	12,829	48,171	283,082	Jun 13 04:38 PM
Pons Jaume	President & CEO	Dec 29	Sale	11.07	3,232	35,779	539,746	Jan 03 08:29 PM
Randolph Sophia	Chief Medical Officer	Dec 29	Sale	11.07	1,617	17,901	270,253	Jan 03 08:47 PM
GARCIA PETER S	Chief Financial Officer	Dec 29	Sale	11.07	893	9,886	53,723	Jan 03 08:34 PM
Pinto Shelly	VP, Finance and CAO	Dec 29	Sale	11.07	482	5,336	62,097	Jan 03 08:52 PM
Randolph Sophia	Chief Medical Officer	Dec 16	Option Exercise	4.09	46,474	189,875	271,870	Dec 20 05:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALXO

Alx Oncology Holdings Inc

Upgrade your FINVIZ experience